- Projects & figures
- News & Events
- Managing your project
- About ERC
Spacecraft follow the same tendency as our computers to become continuously smaller, but more connected. In his ERC grant “NetSat”, Klaus Schilling, from the Zentrum für Telematik in Würzburg, studies control strategies for small pico-satellites in formation, in order to achieve the best performance through their cooperation.
The deep seafloor covers around 70% of our planet’s surface and is home to a diverse community of microorganisms, mostly bacteria. These single-cell life forms inhabit some of the most extreme places in the world, with freezing waters, permanent darkness, high pressure and little food. ERC grantee Antje Boetius studies these microbes in the abyss and their important role for the Earth’s nutrient cycles.
Our soils are inhabited by millions of microorganisms; however, the majority of them lay dormant. In her ERC project, Prof. Dagmar Woebken explores the mechanisms that allow soil microorganisms to go into dormancy and thus survive unfavorable conditions. It is further the goal to reveal the environmental signals that lead to their resuscitation to perform important ecosystems functions.
Can highly automated vehicles fare better than traditional cars in traffic gridlock conditions? Cooperation between vehicle intelligent transport systems via connected vehicles may provide a solution.
Will spacecraft follow a similar evolution to computers? While information processing in the last century was performed by large mainframe computers, today, networked smart phones dominate the market. In spacecraft engineering a similar paradigm shift is apparent: from traditional single, large, and multifunctional satellites towards groups of very small satellites that cooperate together. Professor Klaus Schilling, in his ERC project “NetSat”, addresses crucial challenges to enable small satellite formations to self-organise. This offers innovative application perspectives in areas like Earth observation, science exploration or telecommunications.
Prof. Giulio Superti-Furga and his team work on understanding the movement of molecules across human cells. In a paper recently published on Cell Host & Microbe, they outline the significance of a single protein, SLC4A7, in phagocytosis, the body's first line of defence against infection. These results, however, go beyond the context of infectious diseases, with repercussions on our knowledge of processes like inflammation and cancer.
Magdalena Król is Professor at the Faculty of Veterinary Medicine of the Warsaw University of Life Sciences (SGGW) in Poland. She specializes in cancer research. Since 2006 Professor Król and her team have been investigating canine mammary cancer with particular focus on cancer metastasis and tumor microenvironment. Now she develops innovative cell-based method of drug delivery to solid tumors. Her discoveries about interactions between immune cells and cancer cells may one day revolutionize the treatment of cancer.
Originally published in March 2017 as part of the multimedia campaign "ERC - 10 years – 10 portraits."
Antibiotics are amongst the most crucial discoveries in modern medicine. However, the surge in microbial resistance to these, now common, drugs is a challenge that medical researchers work hard to tackle. Prof. Susanne Häußler from the Helmholtz Centre for Infection Research believes early diagnostic tools could shift the paradigm of how we battle this problem.
Parents may threat at the idea of their children playing in fields and sheds, but research shows that those who grew up in farms, where this is common occurrence, are less likely to suffer from allergies and asthma. Prof. Erika von Mutius leads a team of researchers, that uses this knowledge to investigate how we could treat such conditions more effectively.
Thousands of new cases of head-and-neck cancer - which includes cancer of the larynx, throat, mouth, nose and salivary glands - are diagnosed every year in Europe. Despite improvements in diagnostic and therapeutic tools, these malignant tumours still show high resistance to current treatments. Dr Daniela Thorwarth is working on tailored therapies for individual patients.